AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17306441 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel+prednisolone (30 mg m(‐2) weekly during 5 of 6 wk + prednisolone 5 mg x 2 per os daily)
Number of subjects: 109
Study 17306441 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (5 mg x 2 per os daily)
Number of subjects: 109
Study 17306441 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel+prednisolone
Number of subjects: 109
Study 15082979 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (steroid)
Number of subjects: 120
Study 15082979 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 120
Study 11440265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical exam for equinus contracture defined as < or =5 degrees of ankle dorsiflexion
Number of subjects: 68
Study 11440265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical exam for equinus contracture defined as < or =10 degrees of ankle dorsiflexion
Number of subjects: 68
Study 11440265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical exam for no equinus defined as < or =5 degrees of ankle dorsiflexion
Number of subjects: 68
Study 11440265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical exam for no equinus defined as < or =10 degrees of ankle dorsiflexion
Number of subjects: 68
Study 9824787 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 4 mg twice daily
Number of subjects: 13
Study 9824787 — intervention group
Group type: COMPARATOR
Intervention: Tiagabine 4 mg twice daily with Erythromycin 500 mg twice daily
Number of subjects: 13
Study 9824787 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 500 mg twice daily
Number of subjects: 13
Study 7820516 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein patch angioplasty
Number of subjects: 200
Study 7820516 — intervention group
Group type: COMPARATOR
Intervention: Division-endarterectomy-anastomosis
Number of subjects: 200
Study 3262028 — intervention group
Group type: EXPERIMENTAL
Intervention: A-calcitonin-gene-related peptide (10(-11) mol)
Number of subjects: 0
Study 3262028 — intervention group
Group type: EXPERIMENTAL
Intervention: B-calcitonin-gene-related peptide (10(-11) mol)
Number of subjects: 0
Study 3262028 — intervention group
Group type: EXPERIMENTAL
Intervention: A-calcitonin-gene-related peptide (10(-13) mol)
Number of subjects: 0
Study 3262028 — intervention group
Group type: EXPERIMENTAL
Intervention: B-calcitonin-gene-related peptide (10(-13) mol)
Number of subjects: 0
Study 3262028 — intervention group
Group type: EXPERIMENTAL
Intervention: A-calcitonin-gene-related peptide (10(-15) mol)
Number of subjects: 0
Study 3262028 — intervention group
Group type: EXPERIMENTAL
Intervention: B-calcitonin-gene-related peptide (10(-15) mol)
Number of subjects: 0
Study 31563372 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR) for 60 seconds
Number of subjects: 25
Study 31563372 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR) for 120 seconds
Number of subjects: 25
Study 31563372 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling Massage (RM) for 60 seconds
Number of subjects: 25
Study 31563372 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling Massage (RM) for 120 seconds
Number of subjects: 25
Study 26481198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 IU/week for 6 weeks, then 60,000 IU/month for 3 months)
Number of subjects: 150
Study 26481198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 150
Study 26200237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2898
Study 26200237 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2898
Study 26200237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2898
Study 23549954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (0.8 ± 0.1 mg/kg per day for 3 days; cycles per year 2.0 ± 0.1; duration 7.3 ± 1.1 years; n = 5)
Number of subjects: 9
Study 23549954 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 4)
Number of subjects: 9
Study 23549954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate
Number of subjects: 9
Study 23549954 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 9
Study 22052309 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFT-2
Number of subjects: 709
Study 22052309 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFT-1
Number of subjects: 709
Study 22052309 — intervention group
Group type: COMPARATOR
Intervention: Vehicle 2 weeks
Number of subjects: 709
Study 22052309 — intervention group
Group type: COMPARATOR
Intervention: Vehicle 4 weeks
Number of subjects: 709
Study 19394939 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA (2g/day) for 12 weeks
Number of subjects: 50
Study 19394939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16968960 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of pantoprazole
Number of subjects: 0
Study 16968960 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of pantoprazole
Number of subjects: 0
Study 15471756 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet questionnaire (n=221)
Number of subjects: 442
Study 15471756 — intervention group
Group type: COMPARATOR
Intervention: Mailed questionnaire (n=221)
Number of subjects: 442
Study 11737514 — intervention group
Group type: EXPERIMENTAL
Intervention: Image analysis system for quantitative plaque measurement
Number of subjects: 15
Study 11737514 — intervention group
Group type: EXPERIMENTAL
Intervention: Image analysis system
Number of subjects: 15
Study 11737514 — intervention group
Group type: COMPARATOR
Intervention: Turesky modification of the Quigley and Hein plaque index
Number of subjects: 15
Study 11737514 — intervention group
Group type: COMPARATOR
Intervention: Addy plaque area index
Number of subjects: 15
Study 9416720 — intervention group
Group type: EXPERIMENTAL
Intervention: M-6-G (Dosage A: 0.015 mg/kg bolus + 0.0072 mg x kg(‐1) x h(‐1) infusion)
Number of subjects: 20
Study 9416720 — intervention group
Group type: EXPERIMENTAL
Intervention: M-6-G (Dosage B: 0.029 mg/kg bolus + 0.014 mg x kg(‐1) x h(‐1) infusion)
Number of subjects: 20
Study 9416720 — intervention group
Group type: EXPERIMENTAL
Intervention: M-6-G (Dosage C: 0.044 mg/kg bolus + 0.022 mg x kg(‐1) x h(‐1) infusion)
Number of subjects: 20
Study 9416720 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (Dosage D: 0.14 mg/kg bolus + 0.05 mg x kg(‐1) x h(‐1) infusion)
Number of subjects: 20
Study 9416720 — intervention group
Group type: EXPERIMENTAL
Intervention: M-6-G combined with morphine (Dosage E: A + D)
Number of subjects: 20
Study 9416720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Dosage F)
Number of subjects: 20
Study 8237837 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 700
Study 8237837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 3307097 — intervention group
Group type: EXPERIMENTAL
Intervention: Kelfiprim (KP)
Number of subjects: 76
Study 3307097 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (CO)
Number of subjects: 76
Study 12095079 — intervention group
Group type: COMPARATOR
Intervention: 10 mg procyclidine
Number of subjects: 28
Study 12095079 — intervention group
Group type: COMPARATOR
Intervention: 15 mg procyclidine
Number of subjects: 28
Study 30343653 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile teledermoscopy (diagnosis using a phone camera)
Number of subjects: 113
Study 30343653 — intervention group
Group type: EXPERIMENTAL
Intervention: Results reviewed by a dermatologist
Number of subjects: 113
Study 30343653 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased chance of detecting melanoma from 65-75% to 95%
Number of subjects: 113
Study 27861362 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (3.25 mg/kg, 4 mg/mL)
Number of subjects: 80
Study 27861362 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 80
Study 24760974 — intervention group
Group type: EXPERIMENTAL
Intervention: 30En%‐protein condition
Number of subjects: 58
Study 24760974 — intervention group
Group type: COMPARATOR
Intervention: 5En%‐protein condition
Number of subjects: 58
Study 24760974 — intervention group
Group type: EXPERIMENTAL
Intervention: 15En%‐protein condition
Number of subjects: 58
Study 22284892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMCs)
Number of subjects: 30
Study 22284892 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded bone marrow cells enriched in CD90+ cells (TRCs)
Number of subjects: 30
Study 22284892 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BMCs and TRCs
Number of subjects: 30
Study 19660910 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation (6.3g daily for 6 weeks)
Number of subjects: 52
Study 19660910 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 52
Study 19091084 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Outcomes Study Sleep Scale (MOS-Sleep)
Number of subjects: 396
Study 16476256 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA baths (photosensitizer 8‐methoxypsoralen at a concentration of 2.6 mg/l)
Number of subjects: 167
Study 16476256 — intervention group
Group type: COMPARATOR
Intervention: NBUVB radiation
Number of subjects: 167
Study 12145014 — intervention group
Group type: COMPARATOR
Intervention: 12 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 18
Study 12145014 — intervention group
Group type: COMPARATOR
Intervention: 20 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 18
Study 12145014 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 18
Study 12145014 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 18
Study 12145014 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 18
Study 10548613 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO(2)) uterine distension
Number of subjects: 30
Study 10548613 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (N/Saline) uterine distension
Number of subjects: 30
Study 10548613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CO(2) and N/Saline distension
Number of subjects: 30
Study 7888365 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice daily
Number of subjects: 20
Study 7888365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2359062 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 58
Study 2359062 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ritodrine hydrochloride
Number of subjects: 58
Study 2359062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 58
Study 349689 — intervention group
Group type: EXPERIMENTAL
Intervention: Insadol (medicament group)
Number of subjects: 0
Study 349689 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31121581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 268
Study 31121581 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 268
Study 27296780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound visual feedback treatment
Number of subjects: 12
Study 27296780 — intervention group
Group type: COMPARATOR
Intervention: Treatment without ultrasound visual feedback
Number of subjects: 12
Study 27241116 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles
Number of subjects: 140
Study 27241116 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 23889363 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (sports performance drink)
Number of subjects: 12
Study 23889363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo (fatigue-inducing drink)
Number of subjects: 12
Study 23889363 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 22190162 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute recovery after heavy resistance exercise (5 deadlift repetitions at 85% 1RM)
Number of subjects: 10
Study 22190162 — intervention group
Group type: COMPARATOR
Intervention: Control trial with no prior heavy resistance exercise (PHRE)
Number of subjects: 10
Study 20124187 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib + Trastuzumab
Number of subjects: 296
Study 20124187 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib alone
Number of subjects: 296
Study 18554393 — intervention group
Group type: EXPERIMENTAL
Intervention: Looking for Meaning intervention (12-session preventive intervention)
Number of subjects: 0
Study 18554393 — intervention group
Group type: COMPARATOR
Intervention: 20-minute video movie (control condition)
Number of subjects: 0
Study 16101614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention booklet
Number of subjects: 450
Study 16101614 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment for postpartum visit
Number of subjects: 450
Study 16101614 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on maternal health
Number of subjects: 450
Study 16101614 — intervention group
Group type: EXPERIMENTAL
Intervention: University education
Number of subjects: 450
Study 12913401 — intervention group
Group type: EXPERIMENTAL
Intervention: Early eptifibatide administration (in the Emergency Department, n = 27)
Number of subjects: 55
Study 12913401 — intervention group
Group type: COMPARATOR
Intervention: Late eptifibatide administration (12-24 h, n = 28)
Number of subjects: 55
Study 12913401 — intervention group
Group type: EXPERIMENTAL
Intervention: Early eptifibatide administration
Number of subjects: 55
Study 12913401 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and late eptifibatide administration
Number of subjects: 55
Study 10077300 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physical exercise for induction of general symptoms
Number of subjects: 64
Study 10077300 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipment causing itching through skin irritation
Number of subjects: 64
Study 10077300 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise combined with equipment causing itching through skin irritation
Number of subjects: 64
Study 10077300 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 64
Study 7560365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride (F‐) concentrations in unstimulated saliva
Number of subjects: 0
Study 7560365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride (F‐) concentrations in stimulated saliva
Number of subjects: 0
Study 7560365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride (F‐) applications
Number of subjects: 0
Study 1600595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (400 mg/m2 given i.v. on day -7)
Number of subjects: 0
Study 1600595 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (timing varied: 5, 7, or 9 days before melphalan)
Number of subjects: 0
Study 4065193 — intervention group
Group type: EXPERIMENTAL
Intervention: L-644,122 administered intravenously to healthy volunteers
Number of subjects: 8
Study 4065193 — intervention group
Group type: EXPERIMENTAL
Intervention: L-644,122 administered by mouth to mild hypertensives
Number of subjects: 8
Study 4065193 — intervention group
Group type: COMPARATOR
Intervention: Low dose intravenous L-644,122
Number of subjects: 8
Study 31859706 — intervention group
Group type: EXPERIMENTAL
Intervention: MEL nanoparticles
Number of subjects: 60
Study 31859706 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine gluconate (CHX)
Number of subjects: 60
Study 30290275 — intervention group
Group type: EXPERIMENTAL
Intervention: My Diabetes Profile (MDP) program
Number of subjects: 0
Study 30290275 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study 26334188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline (HS)
Number of subjects: 68
Study 26334188 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 68
Study 26334188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HS and NS
Number of subjects: 68
Study 24836655 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 260
Study 24836655 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrodesis
Number of subjects: 260
Study 24836655 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 260
Study 23828659 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated probabilistic method
Number of subjects: 59
Study 23828659 — intervention group
Group type: COMPARATOR
Intervention: Naranjo algorithm
Number of subjects: 59
Study 23828659 — intervention group
Group type: COMPARATOR
Intervention: Liverpool algorithm
Number of subjects: 59
Study 23828659 — intervention group
Group type: COMPARATOR
Intervention: Consensual expert judgement
Number of subjects: 59
Study 21285287 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 26
Study 19247686 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (aerobic treadmill exercise in LBNP chamber + flywheel resistive training)
Number of subjects: 16
Study 19247686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 16
Study 19247686 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 16
Study 19247686 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 18179758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-supervised program of chest physical therapy (13 patients)
Number of subjects: 24
Study 18179758 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 patients)
Number of subjects: 24
Study 15131541 — intervention group
Group type: EXPERIMENTAL
Intervention: tenectaplase monotherapy
Number of subjects: 120
Study 15131541 — intervention group
Group type: EXPERIMENTAL
Intervention: combination therapy with low-dose tenectaplase and eptifibatide
Number of subjects: 120
Study 11177662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular beta-radiotherapy
Number of subjects: 0
Study 11177662 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged antiplatelet therapy (6 months or more)
Number of subjects: 0
Study 11177662 — intervention group
Group type: EXPERIMENTAL
Intervention: Broader radiation coverage of the intervention site
Number of subjects: 0
Study 11177662 — intervention group
Group type: COMPARATOR
Intervention: Gamma radiation
Number of subjects: 0
Study 10048176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone monotherapy (n = 135)
Number of subjects: 420
Study 10048176 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone in combination with other agents (n = 235)
Number of subjects: 420
Study 10048176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone monotherapy
Number of subjects: 420
Study 10048176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone treatment
Number of subjects: 420
Study 8583094 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms bolus i.v. followed by 25 micrograms/h i.v. for 3 days
Number of subjects: 54
Study 8583094 — intervention group
Group type: EXPERIMENTAL
Intervention: Heater probe thermocoagulation (HPT)
Number of subjects: 54
Study 8583094 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 100 mg i.v. every 12 h
Number of subjects: 54
Study 2147631 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg day-1
Number of subjects: 8
Study 2147631 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 8
Study 7240557 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise/decay time of at least 200 ms
Number of subjects: 0
Study 7240557 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise/decay times shorter than 200 ms
Number of subjects: 0
Study 7240557 — intervention group
Group type: EXPERIMENTAL
Intervention: Very short rise/decay times
Number of subjects: 0
Study 30932719 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-181
Number of subjects: 1827
Study 30932719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1827
Study 28402342 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless protocol
Number of subjects: 52
Study 28402342 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap protocol
Number of subjects: 52
Study 28402342 — intervention group
Group type: COMPARATOR
Intervention: Flapless and flap protocol
Number of subjects: 52
Study 25576136 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 33
Study 25576136 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 33
Study 23645227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein/zeaxanthin, 10mg/2mg
Number of subjects: 4203
Study 23645227 — intervention group
Group type: COMPARATOR
Intervention: No lutein/zeaxanthin (placebo)
Number of subjects: 4203
Study 21450643 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient cardiac rehabilitation (Rehab)
Number of subjects: 1474
Study 21450643 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Hosp)
Number of subjects: 1474
Study 19969181 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling microelectrode in the tibialis anterior
Number of subjects: 16
Study 19969181 — intervention group
Group type: COMPARATOR
Intervention: Twitch interpolation technique without a microelectrode
Number of subjects: 16
Study 19969181 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback provided
Number of subjects: 16
Study 18693804 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 2 ADEs
Number of subjects: 0
Study 18693804 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 1 ADE
Number of subjects: 0
Study 18693804 — intervention group
Group type: COMPARATOR
Intervention: Patients with no ADEs
Number of subjects: 0
Study 18693804 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ADE
Number of subjects: 0
Study 15234277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cevimeline, 20 mg three times daily
Number of subjects: 60